{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:19Z","timestamp":1794047479162,"version":"4.8.0"},"reference-count":10,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286140","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:34:18Z","timestamp":1724294058000},"page":"13-15","source":"Crossref","is-referenced-by-count":0,"title":["LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting"],"prefix":"10.3324","volume":"110","author":[{"given":"Miguel","family":"Quijada-\u00c1lamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin","family":"Wagenblast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"70460","doi-asserted-by":"crossref","unstructured":"Minhajuddin M, Winters A, Ye H. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax\/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025; 110(1):103-116.","DOI":"10.3324\/haematol.2023.284716"},{"key":"70461","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"70462","doi-asserted-by":"crossref","unstructured":"Copland M, Hamilton A, Elrick LJ. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539.","DOI":"10.1182\/blood-2005-07-2947"},{"key":"70463","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Mu H. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016; 8(355):355.","DOI":"10.1126\/scitranslmed.aag1180"},{"key":"70464","doi-asserted-by":"crossref","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021; 138(13):1120-1136.","DOI":"10.1182\/blood.2020006785"},{"key":"70465","doi-asserted-by":"crossref","unstructured":"Goff DJ, Recart AC, Sadarangani A. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013; 12(3):316-328.","DOI":"10.1016\/j.stem.2012.12.011"},{"key":"70466","doi-asserted-by":"crossref","unstructured":"Adnan-Awad S, Kankainen M, Mustjoki S. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma. 2021; 62(9):2064-2078.","DOI":"10.1080\/10428194.2021.1894652"},{"key":"70467","doi-asserted-by":"crossref","unstructured":"Hughes TP, Mauro MJ, Cortes JE. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019; 381(24):2315-2326.","DOI":"10.1056\/NEJMoa1902328"},{"key":"70468","doi-asserted-by":"crossref","unstructured":"Moujalled DM, Hanna DT, Hediyeh-Zadeh S. Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Adv. 2020; 4(12):2762-2767.","DOI":"10.1182\/bloodadvances.2019001416"},{"key":"70469","doi-asserted-by":"crossref","unstructured":"Parry N, Busch C, A\u00dfmann V. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discov. 2022; 8(1):457.","DOI":"10.1038\/s41420-022-01211-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286140\/77473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286140\/77932","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11732\/77473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:12Z","timestamp":1794046032000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286140","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}